|
NEW DELHI, Aug. 18, 2025 /PRNewswire/ -- Manipal Hospitals, one of India's leading and globally recognized healthcare institutions, welcomes one of India's most renowned robotic oncosurgeons, Dr. Surender Kumar Dabas as Chairman – Manipal Comprehensive Cancer Centre and Onco Robotic Surgeries, North-West Cluster. With this addition, the hospital across Delhi, Gurugram and Ghaziabad further reinforces its vision to be a destination for world-class cancer care, catering to patients across India as well as international geographies.
Dr. Surender Dabas brings with him more than 22 years of experience in surgical oncology and has been a pioneer in the field of robotic head and neck cancer surgery. Over the years, he has performed over 30,000 cancer surgeries, including more than 4,000 robot-assisted procedures, making him one of the most experienced robotic oncosurgeons in India. His expertise spans robot-assisted surgeries for head and neck cancer, thoracic cancer, gynaecologic malignancies, urological cancer, gastrointestinal and colorectal cancer, and breast cancer.
Welcoming the doctor, Mr. Pramod Alagharu, Regional COO North-West Cluster, Manipal Hospitals, said, "We are proud to welcome Dr. Surender Dabas and his strong team of 150 medical experts. With his specialized expertise in managing complex cancer procedures, Dr. Dabas brings immense value to our commitment to delivering world-class healthcare, including robot-assisted cancer treatment. His leadership will strengthen our role as a preferred destination for complex oncology cases for both domestic and international patients."
Speaking about his new role, Dr. Surender Kumar Dabas, Chairman - Manipal Comprehensive Cancer Centre and Onco Robotic Surgeries, North-West Cluster added, "I am excited to join the Manipal family, one of the largest healthcare networks in India, which has a long-standing reputation for excellence in healthcare. My goal is to build on a strong foundation here and bring the most advanced and precise cancer care to both national and international patients. Through the use of robotics and newer technologies, we aim to make surgeries safer, less invasive, and more effective, improving both survival and quality of life for our patients."
With Dr. Dabas leading the Manipal Comprehensive Cancer Centre, the hospital is poised to emerge as a centre of excellence in comprehensive cancer care, offering advanced clinical protocols, evidence-based treatment, and a multidisciplinary approach to managing cancer. This will further position Manipal Hospitals as a trusted partner for international patients seeking high-quality, technology-led cancer treatment in India.
For any inquiries, contact our team at query.mhd@manipalhospitals.com or call us +91 8527388881.
About Manipal Hospitals
As a pioneer in healthcare, Manipal Hospitals is among the top healthcare providers in India serving over 7 million patients annually. Its focus is to develop an affordable, high-quality healthcare framework through its multispecialty and tertiary care delivery spectrum and further extend it to out-of-hospital care. With the completion of the acquisition of Medica Synergie hospitals and AMRI Hospitals Limited (acquired in Sept 2023), the integrated network today has a pan-India footprint of 38 hospitals across 19 cities with 10,500+ beds and a talented pool of 7,200+ doctors and an employee strength of over 20,500.
Manipal Hospitals provides comprehensive curative and preventive care for a multitude of patients from around the globe. Manipal Hospitals is NABH and AAHRPP accredited, and most of the hospitals in its network are NABL, ER, and Blood Bank accredited and recognized for Nursing Excellence. Manipal Hospitals has also been recognized as the most respected and patient-recommended hospital in India through various consumer surveys.
NEW DELHI, Aug. 18, 2025 /PRNewswire/ -- Manipal Hospitals, one of India's leading and globally recognized healthcare institutions, welcomes one of India's most renowned robotic oncosurgeons, Dr. Surender Kumar Dabas as Chairman – Manipal Comprehensive Cancer Centre and Onco Robotic Surgeries, North-West Cluster. With this addition, the hospital across Delhi, Gurugram and Ghaziabad further reinforces its vision to be a destination for world-class cancer care, catering to patients across India as well as international geographies.
Dr. Surender Dabas brings with him more than 22 years of experience in surgical oncology and has been a pioneer in the field of robotic head and neck cancer surgery. Over the years, he has performed over 30,000 cancer surgeries, including more than 4,000 robot-assisted procedures, making him one of the most experienced robotic oncosurgeons in India. His expertise spans robot-assisted surgeries for head and neck cancer, thoracic cancer, gynaecologic malignancies, urological cancer, gastrointestinal and colorectal cancer, and breast cancer.
Welcoming the doctor, Mr. Pramod Alagharu, Regional COO North-West Cluster, Manipal Hospitals, said, "We are proud to welcome Dr. Surender Dabas and his strong team of 150 medical experts. With his specialized expertise in managing complex cancer procedures, Dr. Dabas brings immense value to our commitment to delivering world-class healthcare, including robot-assisted cancer treatment. His leadership will strengthen our role as a preferred destination for complex oncology cases for both domestic and international patients."
Speaking about his new role, Dr. Surender Kumar Dabas, Chairman - Manipal Comprehensive Cancer Centre and Onco Robotic Surgeries, North-West Cluster added, "I am excited to join the Manipal family, one of the largest healthcare networks in India, which has a long-standing reputation for excellence in healthcare. My goal is to build on a strong foundation here and bring the most advanced and precise cancer care to both national and international patients. Through the use of robotics and newer technologies, we aim to make surgeries safer, less invasive, and more effective, improving both survival and quality of life for our patients."
With Dr. Dabas leading the Manipal Comprehensive Cancer Centre, the hospital is poised to emerge as a centre of excellence in comprehensive cancer care, offering advanced clinical protocols, evidence-based treatment, and a multidisciplinary approach to managing cancer. This will further position Manipal Hospitals as a trusted partner for international patients seeking high-quality, technology-led cancer treatment in India.
For any inquiries, contact our team at query.mhd@manipalhospitals.com or call us +91 8527388881.
About Manipal Hospitals
As a pioneer in healthcare, Manipal Hospitals is among the top healthcare providers in India serving over 7 million patients annually. Its focus is to develop an affordable, high-quality healthcare framework through its multispecialty and tertiary care delivery spectrum and further extend it to out-of-hospital care. With the completion of the acquisition of Medica Synergie hospitals and AMRI Hospitals Limited (acquired in Sept 2023), the integrated network today has a pan-India footprint of 38 hospitals across 19 cities with 10,500+ beds and a talented pool of 7,200+ doctors and an employee strength of over 20,500.
Manipal Hospitals provides comprehensive curative and preventive care for a multitude of patients from around the globe. Manipal Hospitals is NABH and AAHRPP accredited, and most of the hospitals in its network are NABL, ER, and Blood Bank accredited and recognized for Nursing Excellence. Manipal Hospitals has also been recognized as the most respected and patient-recommended hospital in India through various consumer surveys.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
India's leading healthcare network Manipal Hospitals welcomes India's leading cancer specialist Dr. Surender Kumar Dabas to strengthen robotic cancer care in Delhi NCR
|
- The company highlights its approach to integrating real-time data analytics with automated PCR infrastructure
- The standalone booth features STAgora simulation and an interactive touchscreen experience
- An enhanced CURECA model is presented, illustrating next-generation automated laboratory workflows
- Strong on-site engagement from global healthcare and laboratory professionals, researchers, and industry stakeholders
SEOUL, South Korea, April 20, 2026 /PRNewswire/ -- Seegene, a global molecular diagnostics company, announced that it introduced STAgora™, a real-time data analytics platform based on aggregated statistical testing data, and presented an enhanced model of its automated PCR workflow concept CURECA™ at ESCMID Global 2026 (formerly ECCMID), held April 17–21 in Munich, Germany, drawing interest from healthcare professionals attending the event.
Throughout the exhibition, Seegene's booth drew strong on-site interest from healthcare professionals, laboratory specialists, academic researchers, and industry stakeholders worldwide. Visitors explored the automated PCR workflow at the CURECA station and engaged in discussions about its potential applications. At the STAgora station, attendees experienced live simulations of the platform, demonstrating strong interest in its intuitive interface and aggregated data visualization capabilities.
At the conference, Seegene presented its key message, "From Numbers to Insights", highlighting how automated testing infrastructure and real-time data analytics can work together to support a better understanding of population-level and public health-related trends.
"STAgora is designed to connect PCR testing data generated around the world in real time and provide a clearer view of infectious disease trends based on aggregated statistics," said Young Seag Baeg, New Business Officer at Seegene. "We are continuing to explore how real-time data analytics, combined with automated testing infrastructure, can help laboratories better understand infection patterns and expand the practical use of aggregated testing data."
At the booth, visitors explored real-time dashboards presenting comparative data between single-target and syndromic PCR testing outputs, regional infection trends over time, pathogen-specific positivity rates and co-infection patterns. The ability to analyze aggregated test results alongside regional epidemiological data drew particular attention from attendees.
Seegene also showcased an enhanced model of CURECA. Visitors examined the system's modular structure and automation workflow, which integrates preprocessing, nucleic acid extraction, amplification, and result processing. Many attendees engaged in in-depth discussions about the system's architecture and its applicability in real laboratory environments.
A clinician from a university hospital in Germany who experienced the STAgora demonstration commented that the platform provided a more intuitive way to explore and visualize aggregated testing data trends. The clinician noted that the ability to view regional infection trends alongside aggregated test results in real time was particularly impactful.
"Interest in STAgora's real-time data capabilities and practical applications was strong throughout the event," said Daniel Shin, Executive Vice President and Chief Global Sales and Marketing Officer at Seegene. "We plan to expand pilot programs and collaborative evaluations with healthcare and laboratory institutions to further evaluate the platform and support its potential future adoption."
This approach was also noted to align with syndromic PCR testing, which enables the simultaneous detection of multiple pathogens, supporting broader analysis of aggregated infection patterns across different settings.
Seegene previously introduced STAgora and CURECA to the global diagnostics community at major international conferences including ADLM and ESCMID Global 2025. At ESCMID 2026, the company featured an expanded standalone booth where visitors engaged with STAgora through an interactive touchscreen demonstration zone. An enhanced model of CURECA was also displayed, illustrating the company's vision for future workflow automation.
During the conference, Seegene held discussions with global partners and leading laboratories on the adoption and validation of STAgora and CURECA. The company also hosted dedicated sessions for healthcare and laboratory professionals, particularly in Europe, to present use cases and potential applications of its technologies.
Seegene stated that it plans to further expand collaboration with clinical, academic, and research partners to support the implementation and validation of its data-driven diagnostics platform, with the goal of accelerating real-world adoption across global healthcare settings.
About Seegene
Seegene is a global molecular diagnostics company with more than 25 years of expertise in research, development and manufacturing of syndromic real-time PCR technologies. The company is widely recognized for its proprietary multiplex PCR technology, which enables the simultaneous detection of multiple pathogens in a single test.
A core feature of Seegene's syndromic real-time PCR technology is its ability to detect up to 14 pathogens that cause similar signs and symptoms in a single tube while providing quantitative information to support more efficient clinical decision-making.
Seegene's technological capabilities were demonstrated during the COVID-19 pandemic, when the company supplied more than 340 million COVID-19 tests to over 100 countries worldwide.
Building on its molecular diagnostics expertise, Seegene is expanding beyond assay-based diagnostics to develop an integrated diagnostic ecosystem. The company is advancing new technologies including STAgora™, a real-time diagnostic data analytics platform, and CURECA™, a fully automated PCR system designed to streamline the entire molecular testing workflow.
Through its Technology Sharing Initiative and global partnerships, Seegene aims to broaden access to molecular diagnostics technologies and strengthen global preparedness for infectious diseases.
- The company highlights its approach to integrating real-time data analytics with automated PCR infrastructure
- The standalone booth features STAgora simulation and an interactive touchscreen experience
- An enhanced CURECA model is presented, illustrating next-generation automated laboratory workflows
- Strong on-site engagement from global healthcare and laboratory professionals, researchers, and industry stakeholders
SEOUL, South Korea, April 20, 2026 /PRNewswire/ -- Seegene, a global molecular diagnostics company, announced that it introduced STAgora™, a real-time data analytics platform based on aggregated statistical testing data, and presented an enhanced model of its automated PCR workflow concept CURECA™ at ESCMID Global 2026 (formerly ECCMID), held April 17–21 in Munich, Germany, drawing interest from healthcare professionals attending the event.
Throughout the exhibition, Seegene's booth drew strong on-site interest from healthcare professionals, laboratory specialists, academic researchers, and industry stakeholders worldwide. Visitors explored the automated PCR workflow at the CURECA station and engaged in discussions about its potential applications. At the STAgora station, attendees experienced live simulations of the platform, demonstrating strong interest in its intuitive interface and aggregated data visualization capabilities.
At the conference, Seegene presented its key message, "From Numbers to Insights", highlighting how automated testing infrastructure and real-time data analytics can work together to support a better understanding of population-level and public health-related trends.
"STAgora is designed to connect PCR testing data generated around the world in real time and provide a clearer view of infectious disease trends based on aggregated statistics," said Young Seag Baeg, New Business Officer at Seegene. "We are continuing to explore how real-time data analytics, combined with automated testing infrastructure, can help laboratories better understand infection patterns and expand the practical use of aggregated testing data."
At the booth, visitors explored real-time dashboards presenting comparative data between single-target and syndromic PCR testing outputs, regional infection trends over time, pathogen-specific positivity rates and co-infection patterns. The ability to analyze aggregated test results alongside regional epidemiological data drew particular attention from attendees.
Seegene also showcased an enhanced model of CURECA. Visitors examined the system's modular structure and automation workflow, which integrates preprocessing, nucleic acid extraction, amplification, and result processing. Many attendees engaged in in-depth discussions about the system's architecture and its applicability in real laboratory environments.
A clinician from a university hospital in Germany who experienced the STAgora demonstration commented that the platform provided a more intuitive way to explore and visualize aggregated testing data trends. The clinician noted that the ability to view regional infection trends alongside aggregated test results in real time was particularly impactful.
"Interest in STAgora's real-time data capabilities and practical applications was strong throughout the event," said Daniel Shin, Executive Vice President and Chief Global Sales and Marketing Officer at Seegene. "We plan to expand pilot programs and collaborative evaluations with healthcare and laboratory institutions to further evaluate the platform and support its potential future adoption."
This approach was also noted to align with syndromic PCR testing, which enables the simultaneous detection of multiple pathogens, supporting broader analysis of aggregated infection patterns across different settings.
Seegene previously introduced STAgora and CURECA to the global diagnostics community at major international conferences including ADLM and ESCMID Global 2025. At ESCMID 2026, the company featured an expanded standalone booth where visitors engaged with STAgora through an interactive touchscreen demonstration zone. An enhanced model of CURECA was also displayed, illustrating the company's vision for future workflow automation.
During the conference, Seegene held discussions with global partners and leading laboratories on the adoption and validation of STAgora and CURECA. The company also hosted dedicated sessions for healthcare and laboratory professionals, particularly in Europe, to present use cases and potential applications of its technologies.
Seegene stated that it plans to further expand collaboration with clinical, academic, and research partners to support the implementation and validation of its data-driven diagnostics platform, with the goal of accelerating real-world adoption across global healthcare settings.
About Seegene
Seegene is a global molecular diagnostics company with more than 25 years of expertise in research, development and manufacturing of syndromic real-time PCR technologies. The company is widely recognized for its proprietary multiplex PCR technology, which enables the simultaneous detection of multiple pathogens in a single test.
A core feature of Seegene's syndromic real-time PCR technology is its ability to detect up to 14 pathogens that cause similar signs and symptoms in a single tube while providing quantitative information to support more efficient clinical decision-making.
Seegene's technological capabilities were demonstrated during the COVID-19 pandemic, when the company supplied more than 340 million COVID-19 tests to over 100 countries worldwide.
Building on its molecular diagnostics expertise, Seegene is expanding beyond assay-based diagnostics to develop an integrated diagnostic ecosystem. The company is advancing new technologies including STAgora™, a real-time diagnostic data analytics platform, and CURECA™, a fully automated PCR system designed to streamline the entire molecular testing workflow.
Through its Technology Sharing Initiative and global partnerships, Seegene aims to broaden access to molecular diagnostics technologies and strengthen global preparedness for infectious diseases.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Seegene Introduces STAgora at ESCMID Global 2026, Highlighting Real-Time Data with Automated PCR Workflows
Seegene Introduces STAgora at ESCMID Global 2026, Highlighting Real-Time Data with Automated PCR Workflows
